undefined

Wade T. Iams

Dr. Wade T. Iams from Vanderbilt Ingram Cancer Society Center, co-author of the case report on acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer.

Best podcasts with Wade T. Iams

Ranked by the Snipd community
undefined
Mar 11, 2025 • 6min

A Rare Genetic Shift That Helped Lung Cancer Evade Treatment

Dr. Wade T. Iams, a researcher from the Vanderbilt Ingram Cancer Society Center, dives into the complexities of lung cancer treatment. He discusses a groundbreaking case where a patient developed resistance to lorlatinib due to a rare genetic alteration, RUFY1-RET. This revelation emphasizes the critical role of advanced genetic testing and the necessity for personalized cancer treatments. As cancer evolves, understanding resistance mechanisms becomes vital for effective precision oncology.